Dr Deepa Pakianathan has been in biotech VC for more than twenty years, having seen multiple cycles of biotech boom-and-bust. She gives us her assessment of the IO landscape, her best advice for capital raising and her insight based on how her past experiences with CEOs have informed her approach as a new CEO.
Lead Editorial

The Current State of the IO Fundraising Landscape from a Long-Time Biotech Investor
Featured Editorial
Editorial by Category
Clinical Trial Operations
View All
DPHARM® Announces First Slate of Keynotes for 15th Annual Event

Leveraging AI to Streamline Clinical Development, with Formation Bio’s CDO

How Memorial Sloan Kettering Cancer Center Scaled EHR-to-EDC Technology

Conference Forum Announces the Partnerships with Sites Summit to Improve Patient Enrollment
Immuno-Oncology and Cell Therapy
View AllDrug Delivery
View AllPatients as Partners in Clinical Research and Patient Access
View All
CRO Perspective on Connecting Advocacy and Industry to Advance Patient-Centric Medicine

How Patient Involvement Gets Done to Better Support Access, Decision-making and Medicine Development: Patients as Partners 2025 Recap

What Clinical Research Means to Patients in Ukraine, and How Industry Sponsors Can Help

Biogen on Digital Innovations to Increase Trial Access and Enhance Patient Experiences
Biotech CMO/R&D Leadership
View AllCRAACO: Clinical Research as a Care Option
View All
Conference Forum Announces the Partnerships with Sites Summit to Improve Patient Enrollment

How CMOs can Champion Patient-Centric Drug Development

What Clinical Research Means to Patients in Ukraine, and How Industry Sponsors Can Help

Biogen on Digital Innovations to Increase Trial Access and Enhance Patient Experiences
Women Leadership in Biotech
View All
The Conference Forum Sees Record Growth in Attendees Across 2024 Events, Bringing Together Leaders in Medicine Development

Women Leadership in Immuno-Oncology: 2022 Celebration Series

Women Leadership in Immuno-Oncology: 2021 Celebration Series
